- |||||||||| Levemir (insulin detemir rDNA origin) / Novo Nordisk
PK/PD data, Journal: Comparing the Efficacy of Various Insulin Types: Pharmacokinetic and Pharmacodynamic Modeling of Glucose Clamp Effects in Healthy Volunteers. (Pubmed Central) - Feb 21, 2025
The maximum glucose stimulation ( ) was 163, and the insulin concentration for a half-maximal effect ( ) were 1156 pmol/L for insulin lispro, regular human insulin, neutral protamine hagedorn (NPH) insulin, and insulin glargine; 674 pmol/L for insulin aspart; and 5335 pmol/L for insulin detemir...This mechanism-based glucose-insulin model demonstrated that most insulin analogs exhibit similar receptor- and transporter-related parameters. The model, with specific PK but unified PD parameters, may enable clinical optimization of insulin therapy by highlighting differences in pharmacokinetics and operating common intrinsic glucose utilization parameters.
- |||||||||| Toujeo (Long-acting Recombinant Human Insulin Analogue) / Sanofi, Levemir (insulin detemir rDNA origin) / Novo Nordisk
Journal: Safety and Effectiveness of Glargine 300 U/ml After Switching from Basal Insulins in Patients with Type (Pubmed Central) - Dec 2, 2024
The validated method has been implemented successfully by the Department of Forensic Medicine at our hospital for the investigation of unexplained deaths. Although switching to Gla-300 in poorly controlled PwT1D did not significantly reduce TIR, it significantly decreased HbA1c values and glycemic variability without changes in BW and basal insulin dose.
- |||||||||| Awiqli (insulin icodec) / Novo Nordisk
A Systematic Literature Review and Network Meta Analysis of Insulin Icodec With Other Basal Insulins in Patients With Type 2 Diabetes Switching From Basal-Bolus Insulin Regimens () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_2288;
A SLR was conducted in October 2023, to identify relevant randomised controlled trials (RCTs), examining treatments of interest (insulin icodec, insulin glargine [IGlar U100, IGlar U300], insulin detemir, and insulin degludec) in this population. For patients with T2D switching basal insulin in a basal-bolus regimen, insulin icodec resulted in no significant change in HbA 1c , or proportion of patients experiencing clinically significant hypoglycaemic events, at 26
- |||||||||| Tresiba (insulin degludec) / Novo Nordisk, Levemir (insulin detemir rDNA origin) / Novo Nordisk, Apidra (insulin glulisine) / Sanofi
Journal: Optimization of a mass spectrometric analytical method for the quality assessment of insulin and its analogs. (Pubmed Central) - Aug 17, 2024
The study results demonstrated that MS is a suitable technique for the analysis of biotechnological compounds like insulin and its analogs. Although the obtained results provide an important information regarding this methodology, further studies are needed to validate this analytical approach and check for its suitability to be used in the regulatory environment.
- |||||||||| Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly, Levemir (insulin detemir rDNA origin) / Novo Nordisk
Reactive Eccrine Syringofibroadenoma: A Case Report of a Rare Disease (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_4433;
Multiple anastomosing cords of benign epithelial cells surrounded by a loose fibrovascular stroma can be seen in the histopathological analysis of lesions. ESFA stains positively with epithelial membrane antigen (EMA) and carcinoembryonic antigen (CEA) .
- |||||||||| Preclinical, Journal: Assessment of subcutaneously administered insulins using in vitro release cartridge: Medium composition and albumin binding. (Pubmed Central) - Jul 31, 2024
Albumin-binding acylated insulin analogs exhibited rapid disappearance from the cartridge; however, sustained retention was achieved by coupling albumin to the matrix. An in vitro-in vivorelation was established for the non-albumin-binding insulins.The IVR cartridge is flexible with potential in formulation development as shown by the ability to accommodate solutions, suspensions, and in situ forming formulations while tailoring of the system to probe in vivo relevant medium effects and tissue constituent interactions.
- |||||||||| Stressful Dose Steroids: When Should I Worry About Perioperative Adrenal Insufficiency? (126A) - Jun 25, 2024 - Abstract #ASA2024ASA_2551;
An in vitro-in vivorelation was established for the non-albumin-binding insulins.The IVR cartridge is flexible with potential in formulation development as shown by the ability to accommodate solutions, suspensions, and in situ forming formulations while tailoring of the system to probe in vivo relevant medium effects and tissue constituent interactions. Abstract is embargoed at this time.
- |||||||||| Awiqli (insulin icodec) / Novo Nordisk
Cost-Effectiveness of Insulin Icodec for the Treatment of Type 2 Diabetes (T2D) in Canada (Poster Hall (West A4-B2); 1046) - May 20, 2024 - Abstract #ADA2024ADA_2970;
$45,433 in all analyses, except for the comparison versus IGlar U100 when IIco price is ? IDeg, and versus IGlar U300 when IIco price is = IDeg +10%.At a willingness-to-pay threshold of $50,000/QALY gained, IIco is a cost-effective treatment option for T2D versus once daily basal insulin analogues currently reimbursed in Canada.
- |||||||||| Levemir (insulin detemir rDNA origin) / Novo Nordisk
Trial completion date, Trial primary completion date: IDIOM: Insulin Detemir in Obesity Management (clinicaltrials.gov) - Apr 15, 2024
P=N/A, N=240, Active, not recruiting,
IDeg, and versus IGlar U300 when IIco price is = IDeg +10%.At a willingness-to-pay threshold of $50,000/QALY gained, IIco is a cost-effective treatment option for T2D versus once daily basal insulin analogues currently reimbursed in Canada. Trial completion date: Dec 2023 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Dec 2025
- |||||||||| Afrezza (recombinant human insulin inhalation) / MannKind
Enrollment closed, Trial primary completion date, Combination therapy: Afrezza (clinicaltrials.gov) - Mar 5, 2024
P3, N=319, Active, not recruiting,
Insulin-na Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2024 --> Sep 2024
- |||||||||| Afrezza (recombinant human insulin inhalation) / MannKind
Trial completion date, Combination therapy: Afrezza (clinicaltrials.gov) - Jan 5, 2024
P3, N=264, Recruiting,
Unknown status --> Terminated | N=60 --> 14; recruitment difficulties Trial completion date: Apr 2024 --> Apr 2025
- |||||||||| Tresiba (insulin degludec) / Novo Nordisk, Levemir (insulin detemir rDNA origin) / Novo Nordisk
Review, Journal: The effect of insulin analogs in people with type 1 diabetes at increased risk of severe hypoglycemia. (Pubmed Central) - Dec 13, 2023
However, the absolute treatment differences in the reduction of hypoglycemia are even greater in the trials, including people at high risk of hypoglycemia. This emphasizes the importance of including people at high risk of hypoglycemia to assess the full clinical and pharmacoeconomic benefit of new insulins.
- |||||||||| Afrezza (recombinant human insulin inhalation) / MannKind
Trial primary completion date, Combination therapy: Afrezza (clinicaltrials.gov) - Sep 13, 2023
P3, N=264, Recruiting,
However, insulin detemir was associated with lesser incidence of maternal hypoglycemic events and greater gestational age at delivery, compared to NPH. Trial primary completion date: Aug 2023 --> Dec 2023
- |||||||||| Levemir (insulin detemir rDNA origin) / Novo Nordisk
Journal, HEOR: Changes of health-related quality of life after initiating basal insulin treatment among people with type 2 diabetes. (Pubmed Central) - Sep 1, 2023
Initial insulin regimens of single BI and of basal-bolus (BI included Glargine, Detemir, and Neutral Protamine Hagedorn) accounted for 75.6% and 24.4%, respectively...Basal-bolus has the most significant potential to increase HRQoL, however, the people with diabetes characteristics differ from those initiating BI alone. Further longitudinal cohort study with a longer study period might be necessary to evaluate the certain effect.
- |||||||||| Levemir (insulin detemir rDNA origin) / Novo Nordisk
Journal, HEOR, Real-world evidence, Adherence, Real-world: Real-World Persistence, Adherence, Hypoglycemia, and Health Care Resource Utilization in People With Type 2 Diabetes Who Continued With the Second-Generation Basal Insulin Analog Insulin Glargine 300 Units/mL or Switched to a First-Generation Basal Insulin (Insulin Glargine 100 Units/mL or Detemir 100). (Pubmed Central) - Jul 17, 2023
This study compared treatment persistence, treatment adherence, rates of hypoglycemia, and health care resource utilization outcomes in people with type 2 diabetes who either continued treatment with the second-generation BI Gla-300 or switched to a first-generation BI. The study showed that continuing with Gla-300 was associated with a lower risk of discontinuing therapy, fewer emergency department visits, and lower hypoglycemia event rates than switching to a first-generation BI.
- |||||||||| Levemir (insulin detemir rDNA origin) / Novo Nordisk
Retrospective data, Journal: Insulin Detemir Versus Glibenclamide in Gestational Diabetes Mellitus: A Retrospective Cohort Study. (Pubmed Central) - Jul 3, 2023
The study showed that continuing with Gla-300 was associated with a lower risk of discontinuing therapy, fewer emergency department visits, and lower hypoglycemia event rates than switching to a first-generation BI. In pregnant women with GDM, glucose control on IDet yielded comparable results as on glibenclamide, except for a significantly lower rate of LGA neonates.
- |||||||||| Levemir (insulin detemir rDNA origin) / Novo Nordisk
Preclinical, Journal: Probing the mechanism of reduced in vivo potency of insulin detemir. (Pubmed Central) - Jun 19, 2023
No significant differences were detected with co-infusions of HI with either bacitracin or vehicle. A large proportion of NRMD of IDet which can be inhibited by bacitracin may partly explain the reduced potency of IDet observed in rats and likely also in man.
- |||||||||| Tresiba (insulin degludec) / Novo Nordisk, Levemir (insulin detemir rDNA origin) / Novo Nordisk
Clinical guideline, Review, Journal: Use of basal insulin in the management of adults with type 2 diabetes: An Asia-Pacific evidence-based clinical practice guideline. (Pubmed Central) - Jun 19, 2023
A large proportion of NRMD of IDet which can be inhibited by bacitracin may partly explain the reduced potency of IDet observed in rats and likely also in man. The objective of this study was to provide recommendations regarding effectiveness, safety, optimal starting dose, optimal maintenance dose range, and target fasting plasma glucose of five basal insulins (glargine U-300, degludec U-100, glargine U-100, detemir, and insulin protamine Hagedorn) in insulin-na
- |||||||||| Levemir (insulin detemir rDNA origin) / Novo Nordisk
Trial completion, Trial completion date: CF-IDEA: Cystic Fibrosis - Insulin Deficiency, Early Action (clinicaltrials.gov) - May 31, 2023
P3, N=100, Completed,
The objective of this study was to provide recommendations regarding effectiveness, safety, optimal starting dose, optimal maintenance dose range, and target fasting plasma glucose of five basal insulins (glargine U-300, degludec U-100, glargine U-100, detemir, and insulin protamine Hagedorn) in insulin-na Active, not recruiting --> Completed | Trial completion date: Jun 2023 --> Feb 2023
- |||||||||| Levemir (insulin detemir rDNA origin) / Novo Nordisk
Trial completion: DEES: Detemir Energy Expenditure Study (clinicaltrials.gov) - May 31, 2023
P4, N=30, Completed,
Active, not recruiting --> Completed | Trial completion date: Jun 2023 --> Feb 2023 Unknown status --> Completed
- |||||||||| Insulatard (isophane insulin) / Novo Nordisk, Levemir (insulin detemir rDNA origin) / Novo Nordisk, Novolin R (recombinant human insulin) / Novo Nordisk
Journal: ANALYSIS OF CLINICAL AND LABORATORY PARAMETERS CHILDREN WITH DIABETES MELLIUS TYPE 1 USING DIFFERENT TYPES OF INSULIN PREPARATIONS. (Pubmed Central) - May 15, 2023
Group 1 included 20 children who used Insulin human (Insulatard), group 2 included 15 children using insulin Glargine, and group 3 included 14 children using insulin Detemir...Those using Insulin human (Insulatard) used Human insulin (rDNA, Actrapid) in addition...However, no such relationship between Glargine, body mass and height was recorded. It was a negative correlation between its dose Glargine with glycohemoglobin and also between glucose and cholesterol using Glargine.
- |||||||||| Levemir (insulin detemir rDNA origin) / Novo Nordisk
Misdiagnosing Latent Autoimmune Diabetes Mellitus in Adults: A Case Report (ENDOExpo) - May 11, 2023 - Abstract #ENDO2023ENDO_191;
Type 1 diabetes mellitus or autoimmune diabetes mellitus should always be ruled out if the clinical picture does not match with type 2 Diabetes Mellitus or in a relatively young patient. Our case aims to increase awareness of Autoimmune Polyendocrine syndrome, which occurs as a result of loss of immune tolerance, leading to impairment of multiple endocrine glands.
- |||||||||| Afrezza (recombinant human insulin inhalation) / MannKind
Trial primary completion date, Combination therapy: Afrezza (clinicaltrials.gov) - May 8, 2023
P3, N=264, Recruiting,
This finding provides important reassurance regarding the safety of long-acting insulin analogues with respect to incident DR. Trial primary completion date: Apr 2023 --> Aug 2023
- |||||||||| Tresiba (insulin degludec) / Novo Nordisk, Levemir (insulin detemir rDNA origin) / Novo Nordisk
Journal: Total Chemical Synthesis of Palmitoyl-Conjugated Insulin. (Pubmed Central) - Apr 24, 2023
The palmitoyl-insulin is shown to be structurally similar to insulin and biologically active both in vitro and in vivo. Importantly, unlike native insulin, palmitoyl-insulin is slow and long-acting.
- |||||||||| Toujeo (Long-acting Recombinant Human Insulin Analogue) / Sanofi, Tresiba (insulin degludec) / Novo Nordisk, Levemir (insulin detemir rDNA origin) / Novo Nordisk
Review, Journal: Insulin Therapy in Small Animals, Part 1: General Principles. (Pubmed Central) - Apr 11, 2023
For a formulation to be an effective and safe basal insulin, its action should be roughly the same every hour of the day. Currently, only insulin glargine U300 and insulin degludec meet this standard in dogs, whereas in cats, insulin glargine U300 is the closest option.
- |||||||||| Toujeo (Long-acting Recombinant Human Insulin Analogue) / Sanofi, Tresiba (insulin degludec) / Novo Nordisk, Levemir (insulin detemir rDNA origin) / Novo Nordisk
Review, Journal: Insulin Therapy in Small Animals, Part 3: Dogs. (Pubmed Central) - Apr 11, 2023
In most dogs, good control of clinical signs is achieved when using a basal insulin alone. In a small minority, bolus insulin at the time of at least one meal per day may be added to optimize glycemic control.
- |||||||||| Tresiba (insulin degludec) / Novo Nordisk, Levemir (insulin detemir rDNA origin) / Novo Nordisk, Apidra (insulin glulisine) / Sanofi
Journal: Insulin analogs in the treatment of type II diabetes and future perspectives. (Pubmed Central) - Mar 28, 2023
This review explores the currently available insulin analogs, their clinical implications, pharmacokinetics (PK), pharmacodynamics (PD), safety profile, and cost-effectiveness. We also discuss the future developments in the management of T2DM, especially the scientific advancements surrounding the novel insulin formulations, including the biosimilar insulin, and the innovative insulin delivery methods, such as oral and inhaled insulin.
|
